DAGOBERTO BALDERAS: Open Payments
NPI 1699835843 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,405 in 146 payments from 30 companies in 2025. Trend: 2023 $3,795 · 2024 $3,594 · 2025 $3,405
Food & beverage: $3,379Education: $27
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $629 |
| Amgen Inc. | 19 | $352 |
| AstraZeneca Pharmaceuticals LP | 17 | $331 |
| Lilly USA, LLC | 13 | $279 |
| ABBVIE INC. | 10 | $240 |
| Corcept Therapeutics | 8 | $210 |
| Indivior Inc. | 7 | $168 |
| PFIZER INC. | 5 | $131 |
| TMS NeuroHealth Centers Inc. | 2 | $131 |
| Antares Pharma, Inc. | 5 | $105 |
Products named: Rybelsus, Ozempic, Korlym, OTEZLA, VRAYLAR, SUBLOCADE, AIRSUPRA, REPATHA.
Industry payments across TX — which companies pay providers there.
